Michael Garrett

Michael Garrett

Company: Flamingo Therapeutics

Job title: CEO


Progressing Pre-Clinical & Translational Applicability of Non-Coding RNAs Towards Clinical Development 11:30 am

LncRNA are an attractive new area for oncology therapeutics Antisense oligonucleotides can play a key role in inhibiting lncRNAs First lncRNA ASO identified that is progressing to human clinical trialsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.